Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 8/2015

01-08-2015 | Research Article

MicroRNA-335 represents an independent prognostic marker in cervical cancer

Authors: Changhe Wang, Tao Jiang

Published in: Tumor Biology | Issue 8/2015

Login to get access

Abstract

Advanced stages with distant metastases or recurrence lack reliable prognostic predictor for cervical cancer. Therefore, the purpose of this study was to investigate the clinical significance of miR-335 expression in cervical cancer. A total of 138 cervical cancer samples were collected, and normal cervical tissues were obtained as matched-pair controls. The level of miR-335 expression was examined using quantitative real-time polymerase chain reaction. Overall survival was analyzed using Kaplan–Meier method. Moreover, the relationship between the expression of miR-335 and the clinicopathological features was further analyzed using Cox regression. Lower miR-335 expression was found in cervical cancer specimens. Cervical cancer patients with reduced miR-335 level had shorter survival time, compared with those with high levels of miR-335 expression (P = 0.011, log-rank = 6.458). Through Cox regression, we found that miR-335 expression was associated with the survival of cervical cancer (RR = 0.251, 95 % CI 0.095–0.663, P = 0.005). The results suggested that miR-335 expression was decreased in cervical cancer specimens and lower miR-335 expression resulted in poorer survival in patients with cervical cancer. Our findings indicated that miR-335 may be a candidate factor for predicting prognosis for cervical cancer.
Literature
1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMed
2.
Wei LH. Prevention and treatment of cervical cancer, it is a long-term and arduous task. Zhonghua Fu Chan Ke Za Zhi. 2013;48:304–6.PubMed
3.
Huang EY, Hsu HC, Sun LM, Chanchien CC, Lin H, et al. Prognostic value of pretreatment carcinoembryonic antigen after definitive radiotherapy with or without concurrent chemotherapy for squamous cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 2011;81:1105–13.CrossRefPubMed
4.
Tsai CC, Liu YS, Huang EY, Huang SC, Chang HW, et al. Value of preoperative serum CA125 in early-stage adenocarcinoma of the uterine cervix without pelvic lymph node metastasis. Gynecol Oncol. 2006;100:591–5.CrossRefPubMed
5.
Tsai CC, Lin H, Huang EY, Huang SC, Hsieh CH, et al. The role of the preoperative serum carcinoembryonic antigen level in early-stage adenocarcinoma of the uterine cervix. Gynecol Oncol. 2004;94:363–7.CrossRefPubMed
6.
Hacker NF, Nieberg RK, Berek JS, Leuchter RS, Lucas WE, et al. Superficially invasive vulvar cancer with nodal metastases. Gynecol Oncol. 1983;15:65–77.CrossRefPubMed
7.
Pickel H, Haas J, Lahousen M. Prognostic factors in cervical cancer. Eur J Obstet Gynecol Reprod Biol. 1997;71:209–13.CrossRefPubMed
8.
Jin L, Shen Q, Ding S, Jiang W, Jiang L, et al. Immunohistochemical expression of Annexin A2 and S100A proteins in patients with bulky stage IB-IIA cervical cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2012;126:140–6.CrossRefPubMed
9.
Li Z, Yu CP, Zhong Y, Liu TJ, Huang QD, et al. Sam68 expression and cytoplasmic localization is correlated with lymph node metastasis as well as prognosis in patients with early-stage cervical cancer. Ann Oncol. 2012;23:638–46.CrossRefPubMed
10.
Song C, Zhu S, Wu C, Kang J. Histone deacetylase (HDAC) 10 suppresses cervical cancer metastasis through inhibition of matrix metalloproteinase (MMP) 2 and 9 expression. J Biol Chem. 2013;288:28021–33.CrossRefPubMedPubMedCentral
11.
Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.CrossRefPubMed
12.
Ronchetti D, Lionetti M, Mosca L, Agnelli L, Andronache A, et al. An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Med Genomics. 2008;1:37.CrossRefPubMedPubMedCentral
13.
Shu M, Zhou Y, Zhu W, Zhang H, Wu S, et al. MicroRNA 335 is required for differentiation of malignant glioma cells induced by activation of cAMP/protein kinase A pathway. Mol Pharmacol. 2012;81:292–8.CrossRefPubMed
14.
Shi L, Jiang D, Sun G, Wan Y, Zhang S, et al. miR-335 promotes cell proliferation by directly targeting Rb1 in meningiomas. J Neuro-Oncol. 2012;110:155–62.CrossRef
15.
Huang HY, Cheng YY, Liao WC, Tien YW, Yang CH, et al. SOX4 transcriptionally regulates multiple SEMA3/plexin family members and promotes tumor growth in pancreatic cancer. PLoS One. 2012;7:e48637.CrossRefPubMedPubMedCentral
16.
Heyn H, Engelmann M, Schreek S, Ahrens P, Lehmann U, et al. MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development. Int J Cancer. 2011;129:2797–806.CrossRefPubMed
17.
Dohi O, Yasui K, Gen Y, Takada H, Endo M, et al. Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma. Int J Oncol. 2013;42:411–8.PubMed
18.
Cao J, Cai J, Huang D, Han Q, Chen Y, et al. miR-335 represents an independent prognostic marker in epithelial ovarian cancer. Am J Clin Pathol. 2014;141:437–42.CrossRefPubMed
19.
20.
Xu Y, Zhao F, Wang Z, Song Y, Luo Y, et al. MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1. Oncogene. 2012;31:1398–407.CrossRefPubMed
21.
22.
Jiang W, Chen X, Liao M, Li W, Lian B, et al. Identification of links between small molecules and miRNAs in human cancers based on transcriptional responses. Sci Rep. 2012;2:282.PubMedPubMedCentral
23.
He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522–31.CrossRefPubMed
24.
Babashah S, Soleimani M. The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. Eur J Cancer. 2011;47:1127–37.CrossRefPubMed
25.
Christensen BC, Moyer BJ, Avissar M, Ouellet LG, Plaza SL, et al. A let-7 microRNA-binding site polymorphism in the KRAS 3’ UTR is associated with reduced survival in oral cancers. Carcinogenesis. 2009;30:1003–7.CrossRefPubMedPubMedCentral
26.
Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology. 2007;72:397–402.CrossRefPubMed
27.
Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189–98.CrossRefPubMed
28.
Peng HH, Zhang YD, Gong LS, Liu WD, Zhang Y. Increased expression of microRNA-335 predicts a favorable prognosis in primary gallbladder carcinoma. Onco Targets Ther. 2013;6:1625–30.PubMedPubMedCentral
29.
Ma J, Li N, Guarnera M, Jiang F. Quantification of plasma miRNAs by digital PCR for cancer diagnosis. Biomark Insights. 2013;8:127–36.PubMedPubMedCentral
30.
Yang H, Zhang C, Lu YX, Wu XJ, Yuan L, et al. Construction of has-miR-335 lentiviral vector and verification of the target gene of miR-335. Nan Fang Yi Ke Da Xue Xue Bao. 2012;32:306–11.PubMed
31.
Tome M, Lopez-Romero P, Albo C, Sepulveda JC, Fernandez-Gutierrez B, et al. miR-335 orchestrates cell proliferation, migration and differentiation in human mesenchymal stem cells. Cell Death Differ. 2011;18:985–95.CrossRefPubMed
32.
Lynch J, Fay J, Meehan M, Bryan K, Watters KM, et al. MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-beta signalling pathway. Carcinogenesis. 2012;33:976–85.CrossRefPubMedPubMedCentral
33.
Jiang J, Sun X, Wang W, Jin X, Bo X, et al. Tumor microRNA-335 expression is associated with poor prognosis in human glioma. Med Oncol. 2012;29:3472–7.CrossRefPubMed
Metadata
Title
MicroRNA-335 represents an independent prognostic marker in cervical cancer
Authors
Changhe Wang
Tao Jiang
Publication date
01-08-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 8/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3252-2

Other articles of this Issue 8/2015

Tumor Biology 8/2015 Go to the issue

Research Article

Downregulation of telomerase activity by diclofenac and curcumin is associated with cell cycle arrest and induction of apoptosis in colon cancer

Review

Anticancer drugs for the modulation of endoplasmic reticulum stress and oxidative stress

Retraction Note

Retraction Note to: Calcium/calmodulin-dependent kinase inhibitor induces growth inhibition, cell cycle arrest, and apoptosis in human choriocarcinoma cells

Research Article

The role of tumor suppressor gene SOX11 in prostate cancer

Research Article

A link between cold environment and cancer

Research Article

NFKB1/NFKBIa polymorphisms are associated with the progression of cervical carcinoma in HPV-infected postmenopausal women from rural area
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits